| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $282.2M | — | +7.4% |
| Cost of Revenue | $126.6M | — | +10.5% |
| R&D Expense | $37.3M | — | +5.8% |
| SG&A Expense | $23.7M | — | -2.1% |
| Operating Income | $64.9M | — | +2.8% |
| Pre-tax Income | $69.3M | — | +7.4% |
| Income Tax | $20.0M | — | +67.5% |
| Net Income | $49.3M | — | -6.3% |
| EPS (Basic) | $0.83 | — | -3.5% |
| EPS (Diluted) | $0.82 | — | -3.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $226.1M | -31.2% | +9.8% |
| Accounts Receivable | $227.1M | +5.8% | +7.8% |
| Current Assets | $515.8M | -11.6% | +13.3% |
| Total Assets | $740.5M | -11.8% | +4.6% |
| Current Liabilities | $467.4M | +2.5% | +15.4% |
| Stockholders' Equity | $205.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $84.0M | — | +11.7% |
| Capital Expenditures | $4.1M | — | +360.5% |
| Investing Cash Flow | -$4.1M | — | -360.5% |
| Financing Cash Flow | -$179.4M | — | -31.5% |
| Free Cash Flow | $79.9M | — | +7.5% |
| -16.3% |